Compare VERU & WKHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | WKHS |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 40.3M |
| IPO Year | 1996 | 2008 |
| Metric | VERU | WKHS |
|---|---|---|
| Price | $2.23 | $2.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | $21.00 |
| AVG Volume (30 Days) | ★ 287.7K | 89.1K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.92 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,296,958.00 | $763,173.00 |
| Revenue This Year | N/A | $89.23 |
| Revenue Next Year | N/A | $28.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.53 |
| 52 Week High | $7.33 | $11.80 |
| Indicator | VERU | WKHS |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 50.71 |
| Support Level | $2.11 | $2.81 |
| Resistance Level | $2.67 | $3.34 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 6.77 | 77.13 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.